Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 7/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178611 | 0.94 | TRPV4 (0.45) | TRPV4EGLN2CYP11B1CYP11B2TSHR | |
| SCHEMBL16082317 | 0.84 | TRPV4 (0.52) | TRPV4EGLN2CYP11B1CYP11B2TSHR | |
| SCHEMBL15187864 | 0.83 | TRPV4 (0.38) | TRPV4EGLN2CYP11B1CYP11B2TSHR | |
| SCHEMBL862662 | 0.82 | TRPV4 (0.50) | TRPV4EGLN2CYP11B1CYP11B2TSHR | |
| SCHEMBL31746624 | 0.82 | TRPV4 (0.56) | TRPV4EGLN2CYP11B1CYP11B2 | |
| SCHEMBL1630792 | 0.82 | TRPV4 (0.56) | TRPV4EGLN2CYP11B1CYP11B2 | |
| SCHEMBL1417592 | 0.82 | TRPV4 (0.56) | TRPV4EGLN2CYP11B1CYP11B2TSHR | |
| SCHEMBL30583466 | 0.82 | TRPV4 (0.50) | TRPV4EGLN2CYP11B1CYP11B2TSHR | |
| SCHEMBL10949641 | 0.82 | TRPV4 (0.50) | TRPV4EGLN2CYP11B1CYP11B2 | |
| SCHEMBL9821013 | 0.81 | EGLN2 (0.46) | TRPV4EGLN2CYP11B1CYP11B2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4741389-A1 | KAT6 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4733299-A1 | SULFUR-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Braegen Pharmaceutical Co., Ltd. (CN) | 2026-04-29 | — | — | EP | disclosed |
| EP-3870583-B1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| EP-4694889-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES | Acelot, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4299135-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
| EP-2220073-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010062571-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010059390-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |
| WO-2009063244-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-05-22 | — | — | WO | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
| CN-101374808-A | Indole sulfonamide modulators of progesterone receptors | LILLY CO ELI (US) | 2009-02-25 | — | — | CN | disclosed |
| EP-1979314-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | Eli Lilly & Company (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087488-A9 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007087488-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | TRPV4 2910/4885EGLN2 837/4885CYP11B1 1024/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | TRPV4 1449/4885EGLN2 2039/4885CYP11B1 796/4885 |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | TRPV4 4069/4885EGLN2 1754/4885CYP11B1 1470/4885 |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | PGR, NPSR1, PRLHR | TRPV4 793/4885EGLN2 1257/4885CYP11B1 192/4885 |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | KAT8, KAT5, KAT7 | TRPV4 3638/4885EGLN2 2803/4885CYP11B1 2850/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | TRPV4 909/4885EGLN2 611/4885CYP11B1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.